- Home
- BGH vs KMDA Comparison
BGH vs KMDA Comparison
Compare BGH & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGH
- KMDA
- Stock Information
- Founded
- BGH 2012
- KMDA 1990
- Country
- BGH United States
- KMDA Israel
- Employees
- BGH N/A
- KMDA N/A
- Industry
- BGH Investment Managers
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- BGH Finance
- KMDA Health Care
- Exchange
- BGH Nasdaq
- KMDA Nasdaq
- Market Cap
- BGH 318.8M
- KMDA 349.6M
- IPO Year
- BGH N/A
- KMDA N/A
- Fundamental
- Price
- BGH $15.93
- KMDA $7.08
- Analyst Decision
- BGH
- KMDA Strong Buy
- Analyst Count
- BGH 0
- KMDA 2
- Target Price
- BGH N/A
- KMDA $14.50
- AVG Volume (30 Days)
- BGH 61.5K
- KMDA 143.6K
- Earning Date
- BGH 01-01-0001
- KMDA 03-05-2025
- Dividend Yield
- BGH 10.06%
- KMDA N/A
- EPS Growth
- BGH N/A
- KMDA 124.29
- EPS
- BGH N/A
- KMDA 0.27
- Revenue
- BGH N/A
- KMDA $158,380,000.00
- Revenue This Year
- BGH N/A
- KMDA $15.37
- Revenue Next Year
- BGH N/A
- KMDA $8.58
- P/E Ratio
- BGH N/A
- KMDA $25.99
- Revenue Growth
- BGH N/A
- KMDA 4.52
- 52 Week Low
- BGH $11.92
- KMDA $4.74
- 52 Week High
- BGH $14.50
- KMDA $8.00
- Technical
- Relative Strength Index (RSI)
- BGH 59.03
- KMDA 66.54
- Support Level
- BGH $15.72
- KMDA $7.00
- Resistance Level
- BGH $15.91
- KMDA $7.23
- Average True Range (ATR)
- BGH 0.15
- KMDA 0.32
- MACD
- BGH 0.03
- KMDA 0.04
- Stochastic Oscillator
- BGH 99.98
- KMDA 56.81
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.